مشخصات پژوهش

Chemotherapy is a well-known and effective treatment for different cancers. Chemotherapy drugs can activate multiple signaling pathways and augment the secretion of inflammatory mediators. Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens currently in clinical use.Emerging evidence points to the pleiotropic anticancer activity of DOX. Its cytotoxic effect produced by intercalating with DNA causing breakdown of DNA strand which causes cancer cell apoptosis. Has significant effects on blood cells. It primarily targets cancer cells by interfering with DNA replication, but it also impacts healthy blood cells. One of the notable side effects of doxorubicin is its contribution to chemotherapy-induced anemia. This occurs because doxorubicin can damage red blood cells (RBCs) during infusion, as well as suppress bone marrow function, which reduces the production of new RBCs. Doxorubicin also affects white blood cells (WBCs), leading to immune suppression. It can decrease the number of circulating WBCs, particularly neutrophils, a condition known as neutropenia. This makes patients more susceptible to infections, as their immune system is weakened.